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17-AAG MEDIATED TARGETING OF HSP90 LIMITS TERT ACTIVITY 
IN PERITONEAL SARCOMA RELATED MALIGNANT ASCITES 
BY DOWNREGULATING CYCLIN D1 DURING CELL CYCLE ENTRY
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Aim: Peritoneal or retro-peritoneal sarcomatosis related malignant ascites formation is a rare but serious consequence of the lo-
coregional metastatic event. The present work aimed to study the effect of the Hsp90 inhibitor (17-AAG), an ansamycin analog, 
on cell cycle and DNA replication specific chaperone-clients interaction in the event of peritoneal sarcoma related malignant as-
cites formation in mouse model at the late stage of malignant growth. Methods: We administered 17-AAG, an Hsp90 inhibitor, 
divided doses (330 μg/kg b.w./day for first five days then next ten days with166 μg/kg b.w./day) through intra-peritoneal route 
of inbred Swiss albino mice bearing full grown peritoneal malignant ascites of sarcoma-180. Our study was evaluated by periph-
eral blood hemogram analysis, malignant ascitic cytology, cell viability test, survival time and mitotic indexing. Furthermore, 
flowcytometric HSP90, TERT, CyclinD1, PCNA and GM-CSF expression analysis has been considered for special objective of the 
study. Results: Our experimental efforts reduced the aggressive proliferation of malignant ascites by drastic downregulation of TERT 
and cyclin D1 on the verge of cell cycle entry along with DNA replication processivity factor PCNA by directly modulating their 
folding machinery — heat shock protein 90. Consequently, we observed that malignant ascitic cells became error prone during the 
event of karyokinesis and produced micronucleus containing malignant cells with low viability. Peripheral neutrophilia due to over-
expression of GM-CSF by the peritoneal malignant ascites were also controlled by the treatment with 17-AAG and overall, the 
treatment modality improved the median survival time. Conclusion: Finally we can conclude that 17AAG administration might serve 
as a prospective pharmacological agent for the management of peritoneal sarcoma related malignant ascites and throws light towards 
prolonged survival of the patients concerned.
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Malignant peritoneal ascites formation from 
the primary neoplastic growth is a very critical and 
troublesome medical emergency faced by most of the 
medical and surgical oncologists. In the context of car-
cinomatosis related malignant peritoneal ascites gen-
eration is a common feature [1]. In the modern clinical 
practice, peritoneal or retro peritoneal sarcomatosis 
related malignant ascites formation and its proper 
management is actually less discussed issue. Perito-
neal leiomyosarcoma, liposarcoma, carcinosarcoma 
gastrointestinal stromal tumor and primary perito-
neal spindle cell sarcoma have primitive mesodermal 
origin and can promote peritoneal malignant ascites 
growth [2–5]. One unusual example of the peritoneal 
sarcomatosis is peritoneal Kaposi’s sarcoma in HIV 
patient which can initiate peritoneal malignant ascites 
as a result of metastasis [6]. However, irrespective 
of the peritoneal sarcomatous origin of ascites, the 
main objective of our present study was two folds, 
1) to understand the pathobiology of the peritoneal 
sarcomatosis related ascites formation and 2) to find 
out the proper molecular target for pharmacological 
management of the said pathophysiology.
In this context, very few pharmacological and 
surgical options are available to combat the situation 
properly. Management of peritoneal ascites by locore-
gional treatment is an attractive option as the malignant 
ascites remains confined to the intra-peritoneal cavity 
during most of their natural history. Most of the con-
ventional routes of chemotherapy administration are 
either intravenous or oral which are very effective but 
have high risk of side effects too where loco-regional 
chemotherapeutic treatment can be a better option. 
So to bring down the unwholesome effect on non target 
organs, locoregional chemotherapeutic administration 
should be considered wherever it is possible [7–9]. 
In our study, we also showed the use of intraperitoneal 
route of chemotherapy administration to manage the 
experimentally induced malignant ascites. 
As the drug resistance is a matter of concern 
along with route of drug administration, the choice 
of pharmacological agents and pharmacological target 
to be taken under consideration. The present study 
considers chaperone-Hsp90 which is the main phar-
macological target. Additionally we also consider the 
status of some important Hsp90 specific clients in the 
event of malignant ascites formation and progression. 
In general, chaperones are ubiquitous, highly con-
served proteins which play a major role in the evolution 
of most of the modern proteins [10–12]. Chaperones 
are vital for all kind of cells for their whole lifespan and 
it saves the cells from proteotoxic damages coming 
from the external environment. Besides the assistance 
of folding and refolding of protein, chaperones are 
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also helpful for the cellular remodeling by maintaining 
the cytoplasmic meshwork i.e. microtubular lattice 
[13–15]. Chaperones target newly synthesized pro-
teins, mutant proteins, newly damaged proteins and 
competing cytoplasmic lattice during cellular remodel-
ing. These above mentioned protein machineries are 
collectively referred as “Clients”, which include cell 
surface receptor to various cytokines and huge array 
of protein molecules. In this scenario, pharmaco-
logical targeting of overloaded Hsp90, the molecular 
chaperone, causes simultaneous degradation of client 
proteins via an apparently understood mechanism 
and results in retardation of neoplastic progression 
[16–18]. Here we tried to unearth the mechanistic 
insight of Hsp90 inhibitor i.e. 17-AAG mediated neo-
plastic growth inhibition by modulating telomerase re-
verse transcriptase (TERT) and cyclin D1. Both, TERT 
and Cyclin D1 control cell cycle and cell proliferation 
of normal and neoplastic cells. Previously we reported 
that intraperitoneal administration of vincristine sul-
fate indirectly reduced TERT expression in experi-
mentally induced sarcomatosis by arresting the cells 
at G2/M phase stage of cell cycle [9]. Previously it was 
also reported that 17-AAG inhibit telomerase assem-
bly and activity in vitro in human JR8 melanoma cell 
line [19]. Our present study considered direct target-
ing of TERT in vivo by inhibiting the Hsp90 through 
17-allylamino-17-demethoxygeldanamycin (17-AAG), 
which is a derivative of ansamycin family of antitu-
mor antibiotic — geldanamycin. Currently 17-AAG 
is in Phase II clinical trial. In Phase-I trial, pharmaco-
dynamic activity of the drug was evaluated by mea-
suring Hsp70 activation and/or degradation of CDK4, 
a kinase, which phosphorylates Cyclin D1 [20–24]. 
In normal condition, CDK4 mediated phosphorylation 
of Cyclin D1 promotes cells to complete G1 phase 
of cell cycle and enter in S phase. We wanted to study 
the Cyclin D1 status after 17-AAG administration in the 
context of sarcomatosis related peritoneal ascites 
formation. Our study also addressed the peritoneal 
sarcomatosis related peripheral blood neutrophilia due 
to over expression of GM-CSF by peritoneal malignant 
ascitic sarcoma. We have followed up the possible 
modulation of GM-CSF production after 17-AAG ad-
ministration in the sarcoma bearing mice as GM-CSF 
is one of the clients of Hsp90.
Ultimately, our present study tried to reduce chap-
erone overload in neoplastic condition like experimen-
tally induced sarcomatosis related peritoneal ascites 
in mouse model by geldanamycin derivatives 17-AAG 
and hopefully it will bring some new light to those pa-
tients having aforementioned secondary neoplastic 
complicacy.
MATERIAL AND METHODS
Animals. 10–12 weeks old Swiss albino mice 
(Mus musculus) weighing 20 to 24 g were selected 
from an inbred colony maintained under controlled 
room temperature (22±2°C) in the animal house of our 
institute. During the course of the study the animals 
were fed on a diet consisting of 25.0% protein, 10.0% 
fiber, 5.0% fat, 9.0% minerals and access to water 
ad libitum, under standard conditions with a 12 h light 
dark period. Maximum six animals were housed in cage 
containing sterile paddy husk as bedding through 
out the experiment. The procedures followed were 
in agreement with the approved guide for the care 
and use of laboratory animals and Institutional Animal 
Ethical Committee (IAEC).
Sarcoma-180 transplantation. In this experiment, 
Crocker’s sarcoma (ascitic sarcoma-180) was taken 
as the source of malignant peritoneal ascites develop-
ment. The ascitic fluid was drawn using an 18-gauge 
needle into sterile syringe. 100 μL of ascitic fluid was 
tested for microbial contamination, then viability was 
determined by erythrosin-B exclusion test and cells 
were counted using hemocytometer. The ascitic fluid 
was suitably diluted in sterile phosphate buffer saline 
to get a concentration of 3 × 106 cells/ml of ascitic sus-
pension. This was injected intraperitoneally to obtain 
malignant ascitic effusion within 12 to 14 days. 
Chemotherapy administration in vivo. We have 
used an Hsp90 inhibitor, 17-AAG in two divided doses 
(330 μg/kg b.w./day for first five days then next ten 
days with166 μg/kg b.w./day) through intra-peritoneal 
route of inbred Swiss albino mice bearing full grown 
peritoneal malignant ascites of sarcoma-180 after 
twelve days of inoculation. The above drug administra-
tion schedule with fully developed tumor burden mice 
was considered for mimicking the late stage condition 
of malignant peritoneal ascites complicacy in human 
being regarding any peritoneal or retroperitoneal 
sarcomatosis. 
Peripheral blood hemogram study. We have 
randomly selected experimental and control animals 
from respective cages for blood hemogram profiling. 
Approximately 200 μL of blood was collected in hepa-
rinized vial by tail vein puncture from both the groups 
of animals. The hemoglobin concentration, total white 
blood cells (WBC), red blood cells, platelets, reticu-
locytes and differential WBC count were performed 
as per standard laboratory techniques. 
Malignant ascitic cytology study. Malignant 
peritoneal ascitic fluid was drawn from both 1) control 
untreated malignant ascites bearing animals and 2) 
from 17-AAG treated malignant ascites bearing ani-
mals and washed by phosphate-buffered saline (PBS). 
Slides were prepared to study the cytology without 
damaging the cell membrane stained by Giemsa.
Erythrosin-B dye exclusion study. After 12–
14 days of S-180 inoculation, 1.0 to 2.0 ml of malignant 
ascitic fluid was collected from control and 17-AAG 
treated animals and diluted in PBS to maintain a cell 
density of 1.0×106/ml. The survival rate of tumor cells 
was evaluated by the Erythrosin-B (Sigma) dye ex-
clusion technique using a hemocytometer (Rohem 
India) under an optical binocular light microscope 
(×400 magnification, Olympus).
Survival study. Chemotherapeutic efficacy can 
be accessed by median survival time (MST) and 
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increased life span (%ILs) of tumor bearing animals 
by the following formula.
%ILS = MST of the treated group ─ MST of the 
control group × 100 / MST of the control group
Enhancement of life span (25% and above) 
of treated group over the control was considered 
as effective antitumor response. Additionally, we also 
studied growth pattern of the treated and untreated 
animals at regular interval which helped us to correlate 
the effect of 17-AAG on tumor burden of the animals. 
Mitotic index study. Intraperitoneal treatment 
of 17-AAG might caused metaphase arrest of ma-
lignant peritoneal ascites in the peritoneum within 
90 min of drug administration. Peritoneal ascitic fluid 
was collected by aspiration and washed with normal 
saline (0.9% NaCl) followed by further processing 
in hypotonic solution of 0.075M KCl at 37˚C for about 
15–25 min. Thereafter, cells were treated with acetic-
methanol (1:3) fixative solution following vigorous 
vortexing to avoid the cell coagulation. The process 
was repeated for three times to increase the number 
of fixed cells. Slides were prepared through fixation 
by heat followed by Giemsa staining.
Mitotic indexing:
Mitotic Index (MI) = TDC × 100/TC 
(TDC= Total dividing cells, TC=Total Cell)
Cell cycle analysis. Flowcytometric cell cycle 
pattern was studied from 17-AAG treated and 17-
AAG untreated control cell population by propidium 
iodide staining kit as per manufacturer instruction. 
Here, 20 000 events were analyzed by BD-FACS Cal-
libur (Becton Dickenson, USA), using Cell Quest Pro 
software.
Flowcytometric analysis of malignancy related 
ascites for Hsp90, TERT, CyclinD1, PCNA and GM-
CSF expression. In both the groups Hsp90, TERT, 
Cyclin D1, PCNA and GM-CSF expression pattern 
in peritoneal malignant ascites were studied by 15 min-
utes 1% Para-formaldehyde fixation and permiabiliza-
tion by 90% ice-cold methanol followed by intracellular 
staining as described later. Five samples were incu-
bated for 30 min with 2 μL rabbit anti Hsp90 antibody 
(Cell Signaling Technology, Canada) , rabbit anti TERT 
antibody (Santa Cruz Biotechnology, USA), Anti Cyclin 
D1-FITC tagged antibody (Abcam, UK), PCNA (Santa 
Cruz Biotechnology, USA), and Anti GM-CSF –FITC an-
tibody (Biolegend, USA) respectively followed by addi-
tion of 2 μL anti rabbit IgG-Alexafluor-488 (Invitrogen, 
USA) in untagged primary antibody coupled cells and 
incubated further in dark for 30–35 min. Excess fluo-
rescence was then washed off with PBS. Samples were 
analyzed by BDFACS Callibur (Becton Dickenson, 
USA) using Cell Quest Pro software. 
Statistics. All the value of hemogram, cell viability, 
mitotic index and FACS data were expressed as mean 
± SD (standard deviation). Statistical analysis was 
performed by Paired t Test (2α = 0.05) and each ex-
periment was performed three times.
RESULTS
Peripheral blood. Untreated sarcomatosis re-
lated ascites bearing animals showed leukemia like 
condition during peritoneal sarcoma burden condi-
tion and mostly sudden overshoot of hemoglobin, 
reticulocytes, RBC and WBC count. Mainly, in differ-
ential count, untreated animals showed an unusual 
elevation of neutrophils in comparison to lymphocyte 
population. In the normal Swiss albino strain of mouse, 
peripheral blood comprised of a higher proportion 
of lymphocyte (60–70%) over neutrophils (25–35%). 
On the other hand, treatment with 17-AAG (after 
12 days of experimentally induced peritoneal sarco-
matosis) showed a suppression of sudden neutrophilia 
in the differential count along with normal standards 
of total Hb, Reticulocyte, RBC and WBC count. All 
the results of comparative hemogram were verified 
by Student’s‘t’ test and were statistically significant 
(Fig. 1 a, b, and Table 1). 
a
b
Fig. 1. (a) represented peripheral blood neutrophilia in the un-
treated group of animals with sarcomatosis related malignant 
ascites in peritoneum. Appearance of banded nucleated neu-
trophils in peripheral blood of untreated animals was the mani-
festation of malignant cell mediated GM-CSF over production. 
In contrary, (b) showed almost reversed hematological picture 
in the 17-AAG treated group of animals, which revealed a normal 
neutrophil count along with standard nuclear segmentation 
Malignant ascitic cytology. Light microscopy 
of untreated and 17-AAG treated malignant peritoneal 
sarcomatosis related ascites showed the presence 
of usual large cells with high cytoplasmic to nuclear 
ratio. 17-AAG treated malignant cells showed cytoplas-
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mic-nuclear asynchrony by producing syncytial cells. 
Additionally, a number of micronuclei were observed 
inside the 17-AAG treated syncytial malignant cells. 
Cytoplasmic basophilia was also evident in untreated 
Table1. Peripheral blood hemogram of untreated and 17-AAG treated groups of animals
Parameters 9th days 15th days 18th days 24th days 30th days 45th days
P value (Each ex-
periment repeat-
ed for 3 times)
Hemoglobin (g/dl)
Untreated S-180 animal 16.93±0.34 10.44±0.40 15.64± 0.6 ** ** ** P<0.0001Treated S-180 animal **** 12.75±0.53 11.54±1.0 10.50±0.5 12.60±0.1 12.75±0.2
Reticulocyte (%)
Untreated S-180 animal 1.56±0.1 1.38±0.3 1.42± 0.34 ** ** ** P<0.0001Treated S-180 animal **** 1.26±0.06 0.77± 0.1 1.95±0.3 1.92 0.15 1.68±0.13
Total R Total RBC count (×106 cell/ μL)
Untreated S-180 animal 13.87±0.1 6.16±0.20 6.55±0.30 ** ** ** P<0.001Treated S-180 animal **** 6.54±0.12 3.19±0.11 2.26±0.21 2.88±0.1 4.59±0.05
Total WBC count (×104 cell/μL)
Untreated S-180 animal 7.8±0.5 6.7±0.13 6.7±0.20 ** ** ** P<0.0001Treated S-180 animal **** 5.3±0.21 5.6±0.14 1.94± 0.3 3.96±0.23 4.11±0.5
Differential count (%)
Untreated
P<0.0001
Lymphocyte
Neutrophils 
Eosinophils
Basophiles
Monocyte
10±1.3
87±1.5
0
0
3±0.2
11±2.1
86±2.3
0
0
3±1.1
15±1.24
84±1.5
0
0
1± 0.01
** ** **
Treated
Lymphocyte
Neutrophils 
Eosinophils
Basophiles
Monocyte
****
20±1.2
75±0.5
0
0
5±0.01
28±2.0
71±1.3
0
0
1±0.2
40±0.5
60±0.75
0
0
0
53±2.1
40±1.3
0
0
7±1.2
47±2.0
53±.0.5
0
0
0
Notes: ** Untreated malignant ascites bearing animals more or less survived up to 18 days from 1st day of passaging.**** We started the 17-AAG treatment 
after 12 days of tumor passaging. 
b
d
a
c
Fig. 2. (a) and (b) showed ascites cytology in the untreated group of animals. High cytoplasmic to nuclear ratio was evident from 
(a). Cytoplasmic basophilia was also documented in (b) with a few contaminating lymphocytes. (c) and (d) revealed the ascites 
cytology after 17-AAG treatment, which made malignant sarcoma cells error prone during the event of karyokinesis. Additionally, 
cytoplasmic to nuclear ratio was altered and as a result heterogeneous population of malignant cells appeared in the peritoneum 
of treated animals (c). Faulty karyokinesis was manifested by nuclear-cytoplasmic asynchrony and formation of micronucleus 
containing syncytial cells (d)
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malignant ascites in comparison to 17-AAG treated as-
cites. Furthermore, it was observed that geldanamycin 
treatment also deformed the uniformity of the plasma 
membrane of the experimental cells (Fig. 2 a–d).
Erythrosin-B dye exclusion study for cell viabil-
ity. In comparison to the untreated animals (99.53%± 
0.6) the ascitic cell viability of the 17-AAG treated ani-
mals decreased to 43.71%±1.5 which was statistically 
significant (P < 0.0001) (Fig. 3) and correlated well with 
the efficacy of the 17-AAG treatment.
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Fig. 3. Erythrosin-B dye exclusion test for cell viability as-
sessment revealed that untreated malignant cells were more 
or less 100% viable in comparison to the 17-AAG treated group. 
On an average 44% cells were viable inside the peritoneum of the 
treated group of animals
Survival study. MST and %ILS varied significantly 
in both groups. MST value of untreated group was 
10 days whereas the treated group MST showed 
23 days. The survival range also improved from 
3–11 days in untreated to 14–45 days in the treated 
group. Increased life span (%ILs) was observed in the 
17-AAG treated group (130%) in comparison to the 
untreated group (Table 2).
Table 2. Effect of 17-AAG on MST and % increased life span (%ILS) of treated 
peritoneal sarcomatosis related ascites bearing mice
Groups MST (Days) (Survival range) % ILS
Untreated 10 (3–10) _
17-AAG treated 23 (14–45) 130
Mitotic index of untreated and 17-AAG treated 
peritoneal sarcoma. We designed the present experi-
ment to evaluate the effect of 17-AAG on the tumor cell 
mitosis and chromosome equipartioning mechanism 
during the event of metaphase. The untreated group 
showed 60.57% ± 1.91 MI in comparison to 17-AAG 
treated mice, which had 35.21 ± 1.30% MI (Fig. 4, a, 
b). Most of the cells of the treated group were found 
in the interphase stage of cell cycle in comparison 
to the untreated animals (Fig. 4, b).
Cell cycle analysis. Unlike 0.24% Go/G1 cells 
of untreated malignant ascites, 17AAG treated as-
cites showed 79.98% cells halted in G0/G1 phase. 
On the other hand high percentage of S phase cells 
(92.57%) was evidenced in untreated sample whereas 
17AAG treatment reduced the number of S phase cells 
(18.24%) in treated group of animals. G2/M phase 
specific cells were 7.27% in case of untreated sam-
ple, whereas only 1.98% 17AAG treated cells were 
in G2/M phase stage (Fig. 5).
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Fig. 4. Mitotic index (MI) of untreated group (a) represented 
60.57% cells in mitosis and very negligible amount of cells 
were present in metaphase which demonstrated the rapid cell 
cycling nature of untreated malignant cells. Nearly 38% cells 
were in Interphase stage. (b) revealed the MI of 17-AAG treated 
group where 17-AAG treatment blocked the cells at Interphase 
(65%) and very low amount of cells were at metaphase (7%)
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Fig. 5. Flowcytometric cell cycle study of untreated and 17AAG 
treated malignant ascites. M1, M2 and M3 are representative 
virtual marker of G0/G1, S and G2/M phases respectively
Flowcytometric analysis of Hsp 90 and its cli-
ent proteins. Flowcytometric study of Hsp90, TERT, 
Cyclin D1, PCNA and GM-CSF expression pattern 
in peritoneal malignant sarcoma related ascites in the 
17-AAG treated group showed downregulation of TERT 
(60.01 ± 1.22), cyclin D1(3.32 ± 0.24), PCNA(60.23 ± 
0.02), GM-CSF (61.43 ± 0.4) and Hsp90 (209 ± 2.65) 
expression in comparison to the untreated group 
(TERT (172.90 ± 2.07), cyclin D1 (14.01± 0.2), PCNA 
(73.80 ± 0.1), GM-CSF (70.15 ± 1.2) and Hsp90 ex-
pression (248 ± 2.65)] (Fig. 6 and Table 3 ).
Table 3. Flowcytometrically determined mean fluorescence intensity (MFI) 
values of Hsp90 and its clients represented comparative expression pat-
tern in untreated and treated groups of animals
Target proteins MFI of untreat-ed samples
MFI of treated 
samples
P value (Each experiment 
repeated for 3 times)
Hsp90 209 ± 2.65 46.32 ± 2.1 P<0.0001
TERT 172.90 ± 2.07 60.01 ± 1.22 P=0.0003
Cyclin D1 14.01± 0.2 3.32 ± 0.24 P=0.0001
PCNA 73.80 ± 0.1 60.23 ± 0.02 P<0.0001
GM-CSF 70.15 ± 1.2 61.43 ± 0.4 P<0.0001
DISCUSSION
In the present study we emphasized on the forma-
tion of peritoneal sarcomatosis (sarcoma-180) related 
malignant ascites and its associated pathophysiologies 
in syngenic adult Swiss albino mice. In our previous 
study we already showed that intraperitoneal vincristine 
administration reduced malignant ascite burden inside 
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the murine peritoneum by downregulating cellular 
senescence switch — TERT, a main regulatory com-
ponent of the telomerase enzyme [9]. In corroboration 
with the previous study, here we again targeted TERT 
by a more efficient manner which was related to antago-
nizing Hsp90 by its newly developed pharmacological 
inhibitor-17-AAG. The Hsp90 inhibitor 17-AAG is the 
derivative of ansamycin and it competes with cellular 
ATP to bind at NH2-terminal ATP/ADP binding domain 
of Hsp90 to block its chaperone functions, leading 
to destabilization and proteosomal degradation of the 
client proteins (e.g. TERT, cyclin D1 etc). Deregulation 
of the client’s folding procedure by Hsp90 brought 
a number of direct and indirect consequences inside 
the cells. Our present work also revealed the changes 
step by step in the event like sarcoma related malignant 
ascites development inside the murine peritoneum. 
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Fig. 6. Comparative flowcytometric analysis of Hsp90 and its client 
proteins in the untreated and 17-AAG treated groups of animals
In the untreated group we observed abnormal periph-
eral blood hemogram with a huge overshoot of neutrophil 
population in comparison to lymphocytes. Furthermore 
this peripheral blood neutrophilia was steadily present 
and often, in some experimental animals, lymphocytes 
and other granulocytes were totally replaced by afore-
mentioned neutrophilia in peripheral blood during differ-
ential count. The most possible explanation of the per-
sisting peripheral neutrophilia in ascitic sarcoma bearing 
mice was due to the constant over stimulation of resident 
bone marrow neutrophil population by endogenous 
GM-CSF which was not found in normal condition. The 
overshoot of GM-CSF production as evidenced by FACS 
analysis furthered validated the reason of neutrophilia 
in untreated group. The immature marrow neutrophil 
pool (mostly banded neutrophils) shifted from endosteal 
niche to vascular niche to peripheral blood due to higher 
expression of GM-CSF. The reason behind the over 
expression of GM-CSF by sarcoma cells is still obscure. 
Constitutive expression of any protein is actually the result 
of mutation and these mutated proteins usually crowd the 
cellular environment rapidly. Ramification of the unfolded 
mutated protein is generally managed by over expressed 
Hsp90 in response to oncogenic stress. So, in the present 
study we targeted the Hsp90 by 17-AAG, resulted in de-
regulation in refolding process of GM-CSF by competitive 
binding with Hsp90 and produced faulty unstable non-
functional proteins (GM-CSF) in cellular environment and 
consequently stopped the procedure of over stimulation 
of marrow neutrophil storage. Ultimately the beneficial 
effect of 17-AAG was documented in the post treatment 
hemogram of the treated experimental mice. 
We observed micronucleus formation and nuclear-
cytoplasmic asynchrony in the treated group in com-
parison to the untreated group. Nuclear-cytoplasmic 
asynchrony with more than two nucleoli was due to the 
deregulation at cytokinesis and polyploidy induc-
tion in malignant cells. But, multinucleated cells with 
presence of one or two or three micronuclei and one 
large nucleus were the manifestation of improper as-
sortment of chromosome during metaphase stage. 
It evidenced deregulation of Hsp90 and cytoskeletal 
protein interaction during metaphase in presence 
of Hsp90 inhibitor like 17-AAG. Interestingly no sig-
nificant amounts of malignant cells were found at the 
metaphase stage during the mitosis study and mitotic 
indexing. Our previous study related to vincristine re-
vealed that the vinca alkaloid reduced the mitotic index 
of malignant cells by metaphase blocking mechanism 
[9]. The present study established the decrease 
of MI of the malignant cells without blocking at meta-
phase stage by 17-AAG treatment. However, in com-
parison to the untreated group, treated group showed 
higher percentage of cells at interphase stage which 
was furthered explained by flowcytometric investiga-
tion of cell cycle specific marker protein expression.
We have considered the status of a few important 
cell cycle specific proteins by flow cytometry e.g. 
cyclinD1, PCNA and TERT to clarify the increase of in-
terphase cells. Cyclin D1 was used as G0/G1 phase 
marker. PCNA was used for S-phase specific marker 
where DNA replication takes place and the TERT was 
used as the late S phase to early G2 phase entry 
marker which causes cellular immortality. The 17-AAG 
treated group showed drastic downregulation of Cyclin 
D1 in comparison to the untreated group which signi-
fied the direct competition of Cyclin D1 with 17-AAG 
for the N-terminal of Hsp90 and the remnant unfolded 
Cyclin D1 degraded soon. As a result of Cyclin D1 de-
generation, significant amount of cells were blocked 
at G0/G1 stage which might be the possible reason for 
the increased interphase cell count during MI. 
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A moderate depression of PCNA was observed 
in the treated group in comparison to the untreated 
group. 17-AAG treatment hampered PCNA expression 
and stability during the DNA replication. Downregu-
lated PCNA in 17-AAG treated group also signified that 
very few numbers of cells with active DNA replication 
procedure were present in S phase. The TERT expres-
sion data also added an extra dimension in the context 
of cell cycling status of the treated group. Unlike un-
treated group, treated group showed a sharp down-
regulation of TERT expression, which manifested two 
things: 1) 17-AAG efficiently blocked Hsp90 guided 
client processing mechanism for which cancer cell 
proliferation and self renewed process was under 
limitation as both were being maintained by TERT. 2) 
Low viability of treated peritoneal sarcoma cells due 
to improper DNA end replication. 
In conclusion, we can say that 17-AAG treatment 
mediated controlling of a number of oncoprotein 
expression along with Hsp90 itself increase the life 
expectancy of the treated animals group in compari-
son to untreated one. Targeting Hsp90 by 17-AAG also 
caused overcrowding of misfolded protein in malignant 
cells which ultimately reduced tumor burden in mice 
by diminished tumor cell viability and flowcytometric 
TERT expression study would be considered as a novel 
diagnostic and prognostic tool for sarcoma progression. 
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